ATAI
HEALTHCAREATAI Life Sciences BV
AI Insight
What's Moving ATAI Today?
No stock-specific AI insight has been generated for ATAI yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.15$6.75
$4.13
Fundamentals
Market Cap$1.5B
P/E Ratio—
EPS$-2.84
Dividend Yield—
Dividend / Share—
ROE-378.0%
Profit Margin—
Debt / Equity—
Trading
Volume4.2M
Avg Volume (10D)—
Shares Outstanding368.2M
ATAI News
22 articles- Why AtaiBeckley (ATAI) Is Building Its Valuation Case Around BPL-003’s Phase 3 ReadinessYahoo Finance·Jun 17, 2026
- Wall Street Bullish on AtaiBeckley (ATAI), Here’s WhyYahoo Finance·Jun 16, 2026
- Is AtaiBeckley Inc. (ATAI) the Hidden Penny Stock to Invest In?Yahoo Finance·Jun 13, 2026
- Atai Beckley N.V. (ATAI) A Top Penny Stock to Buy Poised to Build Sustained Clinical and Shareholder ValueYahoo Finance·Jun 7, 2026
- AtaiBeckley nears key clinical catalysts, Jefferies stays positive with repeat ‘Buy’ ratingProactive Investors·Jun 4, 2026
- Is AtaiBeckley’s BPL-003 Phase 3 Launch Altering The Investment Case For AtaiBeckley (ATAI)?Yahoo Finance·Jun 4, 2026
- Assessing AtaiBeckley (ATAI) Valuation After Strong Returns And Elevated Price To Book RatioYahoo Finance·Jun 4, 2026
- AtaiBeckley launches mental health patient impact grant programProactive Investors·May 28, 2026
- AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit OrganizationsYahoo Finance·May 28, 2026
- AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026Yahoo Finance·May 27, 2026
- AtaiBeckley (ATAI) Reports Q1 Financial ResultsYahoo Finance·May 22, 2026
- A Look At AtaiBeckley (ATAI) Valuation As Share Price Momentum And DCF Signal DifferYahoo Finance·May 16, 2026
- AtaiBeckley clinical pipeline advances toward multiple late-stage data catalysts, Jefferies saysProactive Investors·May 13, 2026
- AtaiBeckley targets Q2 start for Phase 3 depression trial as pipeline advancesProactive Investors·May 12, 2026
- AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business UpdateYahoo Finance·May 12, 2026
- AtaiBeckley (ATAI) Reports Positive Phase 2a Results for Social Anxiety Treatment EMP-01Yahoo Finance·May 10, 2026
- Does AtaiBeckley’s (ATAI) EMP-01 Data Hint At A Scalable MDMA Therapy Platform?Yahoo Finance·May 1, 2026
- These 3 Psychedelic Stocks Activated After Trump's Executive OrderMarketbeat·Apr 27, 2026
- AtaiBeckley wins OVID Health Silver Award for patient partnership in psychedelic trialsProactive Investors·Apr 27, 2026
- AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed ResearchYahoo Finance·Apr 27, 2026
- AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety DisorderGlobeNewswire Inc.·Apr 22, 2026
- AtaiBeckley to Participate in Upcoming Needham Healthcare ConferencesGlobeNewswire Inc.·Apr 14, 2026
All 22 articles loaded
Price Data
Open$4.11
Previous Close$4.10
Day High$4.29
Day Low$4.08
52 Week High$6.75
52 Week Low$2.15
52-Week Range
$2.15$6.75
$4.13
Fundamentals
Market Cap$1.5B
P/E Ratio—
EPS$-2.84
Dividend Yield—
Dividend / Share—
ROE-378.0%
Profit Margin—
Debt / Equity—
Trading
Volume4.2M
Avg Volume (10D)—
Shares Outstanding368.2M
About ATAI Life Sciences BV
ATAI Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—